Brain volume loss and no evidence of disease activity over 3 years in multiple sclerosis patients under interferon beta 1a subcutaneous treatment
- 1 January 2019
- journal article
- research article
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 59, 175-178
Abstract
No abstract availableKeywords
Funding Information
- Merck KGaA
This publication has 24 references indexed in Scilit:
- Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosisJournal of Neurology, 2012
- Improving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple SclerosisPLOS ONE, 2011
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta‐analytic approachAnnals of Neurology, 2009
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) studyThe Lancet Neurology, 2009
- Gray matter atrophy is related to long-term disability in multiple sclerosisAnnals of Neurology, 2008
- Focal thinning of the cerebral cortex in multiple sclerosisBrain, 2003
- A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2001